



PRESS RELEASE

Crucell to Present at Goldman Sachs Global Healthcare Conference, June 13, and Needham & Company Biotechnology and Medical Technology Conference, June 15

Leiden, The Netherlands, June 8, 2006 – Crucell N.V. (Euronext, NASDAQ: CRXL) has announced that its Chief Financial Officer, Leonard Kruimer, will present at two conferences in the United States next week.

On June 13 at 7.30 AM Pacific Daylight Time (PDT), Mr Kruimer will present at the Twenty-Seventh Annual Goldman Sachs Global Healthcare Conference in Dana Point, California. A live audio webcast will be available during the presentation, and archived thereafter for a period of up to six months, at http://customer.talkpoint.com/GOLD006/061206a_cs/default.asp?entity=crucell.

On June 15 at 9.00 AM Eastern Daylight Time (EDT) Mr. Kruimer will present at the Fifth Annual Needham and Company Biotechnology and Medical Technology Conference in New York. A live audio webcast will be available during the presentation at www.wsw.com/webcast/needham15/crxl and will be archived for a period of 90 days.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B and a virosomal vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6[®] production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, elsewhere in Europe, and in Korea. The Company employs about 900 people. For more information, please visit www.crucell.com.

For further information please contact:

Crucell N.V.

Harry Suykerbuyk
Director Investor Relations and
Corporate Communications
Tel. +31 (0)71 524 8718
h.suykerbuyk@crucell.com

For Crucell N.V. in the USA:

Redington Inc.
Thomas Redington
Tel. +1 212-926-1733
treddington@redingtoninc.com